Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2017-07-21 | GILD | Gilead Sciences Inc | Alton Gregg H | EVP Comm, Acs ALA, Corp, Med A | S - Sale+OE | $74.00 | -40,000 | 97,488 | -29% | -$2,960,000 | |||||
| D | 2017-07-24 | GNCA | Genocea Biosciences, Inc. | Poole Jonathan | CFO | S - Sale+OE | $6.00 | -45,000 | 39,247 | -53% | -$270,000 | |||||
| D | 2017-07-20 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $18.66 | -15,000 | 0 | -100% | -$279,900 | |||||
2017-07-20 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $18.66 | -6,500 | 112,000 | -5% | -$121,290 | ||||||
2017-07-19 | BIIB | Biogen Inc. | Alexander Susan H | EVP Chief Legal Corp Svc, Sec | S - Sale | $285.00 | -7,758 | 27,232 | -22% | -$2,211,030 | ||||||
2017-07-17 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $19.81 | -3,100 | 105,323 | -3% | -$61,411 | ||||||
2017-07-17 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $14.92 | -6,000 | 382,080 | -2% | -$89,520 | ||||||
2017-07-13 | JUNO | Juno Therapeutics, Inc. | Bratton Douglas K | 10% | S - Sale | $27.00 | -8,000,000 | 9,348,799 | -46% | -$216,000,000 | ||||||
| M | 2017-07-13 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $16.84 | -69,859 | 2,356,576 | -3% | -$1,176,710 | |||||
| D | 2017-07-14 | SGMO | Sangamo Therapeutics, Inc | Herberts Curt A. III | Sr.VP, Chief Business Officer | S - Sale+OE | $10.00 | -15,000 | 20,517 | -42% | -$150,000 | |||||
| M | 2017-07-12 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | Pres, CEO | S - Sale | $20.00 | -15,000 | 186,814 | -7% | -$300,059 | |||||
| M | 2017-07-11 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $16.56 | -31,992 | 2,408,563 | -1% | -$529,938 | |||||
| D | 2017-07-10 | TECH | Bio-Techne Corp | Lucas Roger C | Dir | S - Sale+OE | $116.86 | -100 | 2,170 | -4% | -$11,686 | |||||
| D | 2017-07-10 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $99.89 | -2,500 | 27,305 | -8% | -$249,724 | |||||
| D | 2017-07-10 | KITE | Kite Pharma, Inc. | Butitta Cynthia M | COO | S - Sale+OE | $103.09 | -15,000 | 117,795 | -11% | -$1,546,300 | |||||
2017-07-07 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale | $100.49 | -1,200 | 15,977 | -7% | -$120,583 | ||||||
| D | 2017-07-06 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $103.83 | -2,250 | 31,484 | -7% | -$233,616 | |||||
2017-07-07 | JUNO | Juno Therapeutics, Inc. | Klausner Richard | Dir | S - Sale | $29.39 | -24,000 | 800,985 | -3% | -$705,320 | ||||||
| D | 2017-07-05 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $51.98 | -10,423 | 636,435 | -2% | -$541,807 | |||||
| D | 2017-07-05 | XLRN | Acceleron Pharma Inc | Kumar Ravindra | SVP, Chief Scientific Officer | S - Sale+OE | $32.00 | -937 | 95,327 | -1% | -$29,984 | |||||
| D | 2017-07-05 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale+OE | $32.00 | -34,400 | 65,300 | -35% | -$1,100,800 | |||||
| D | 2017-07-05 | XLRN | Acceleron Pharma Inc | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale+OE | $32.00 | -16,000 | 104,900 | -13% | -$512,000 | |||||
| D | 2017-07-05 | ONCE | Spark Therapeutics, Inc. | Marrazzo Jeffrey D | CEO | S - Sale+OE | $65.00 | -5,669 | 230,000 | -2% | -$368,485 | |||||
2017-07-05 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $16.26 | -4,254 | 2,440,555 | 0% | -$69,170 | ||||||
2017-07-05 | CHRS | Coherus Biosciences, Inc. | Herman Alan C. | Chief Scientific Officer | S - Sale | $15.00 | -600 | 367,350 | 0% | -$9,000 | ||||||
| D | 2017-07-05 | BLUE | Bluebird Bio, Inc. | Sullivan Eric | Principal Accounting Officer | S - Sale+OE | $107.28 | -4,313 | 5,974 | -42% | -$462,706 | |||||
| D | 2017-07-05 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $105.28 | -5,000 | 17,177 | -23% | -$526,395 | |||||
| D | 2017-07-03 | GILD | Gilead Sciences Inc | Martin John C | Exec COB | S - Sale+OE | $71.00 | -73,333 | 3,126,636 | -2% | -$5,206,892 | |||||
2017-07-03 | GILD | Gilead Sciences Inc | Alton Gregg H | EVP Comm, Acs ALA, Corp, Med A | S - Sale | $71.06 | -5,000 | 102,988 | -5% | -$355,295 | ||||||
| D | 2017-07-03 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Development | S - Sale+OE | $104.32 | -10,000 | 21,071 | -32% | -$1,043,201 | |||||
| D | 2017-07-03 | JUNO | Juno Therapeutics, Inc. | Harr Steve | CFO, Head, Corp. Development | S - Sale+OE | $30.00 | -8,750 | 727,439 | -1% | -$262,500 | |||||
| D | 2017-07-03 | AVXS | Avexis, Inc. | Nagendran Sukumar | SVP, Chief Medical Officer | S - Sale+OE | $81.88 | -1,780 | 0 | -100% | -$145,748 | |||||
| M | 2017-06-28 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $16.90 | -43,202 | 2,444,809 | -2% | -$730,125 | |||||
| D | 2017-06-29 | BLUE | Bluebird Bio, Inc. | Sullivan Eric | Principal Accounting Officer | S - Sale+OE | $108.96 | -6,787 | 6,707 | -50% | -$739,530 | |||||
| D | 2017-06-27 | JUNO | Juno Therapeutics, Inc. | Harr Steve | CFO, Head, Corp. Development | S - Sale+OE | $30.00 | -8,750 | 727,439 | -1% | -$262,501 | |||||
| D | 2017-06-27 | ONCE | Spark Therapeutics, Inc. | High Katherine A | See Remarks | S - Sale+OE | $60.96 | -10,000 | 210,000 | -5% | -$609,600 | |||||
| D | 2017-06-29 | ONCE | Spark Therapeutics, Inc. | Faga Daniel | Chief Business Officer | S - Sale+OE | $62.71 | -4,500 | 0 | -100% | -$282,195 | |||||
2017-06-27 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $108.05 | -25,000 | 366,554 | -6% | -$2,701,164 | ||||||
2017-06-26 | BOLD | Audentes Therapeutics, Inc. | Lange Louis G | Dir | S - Sale | $19.78 | -15,000 | 596,933 | -2% | -$296,682 | ||||||
| M | 2017-06-26 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $17.08 | -81,435 | 2,488,011 | -3% | -$1,390,611 | |||||
| AD | 2017-06-23 | KITE | Kite Pharma, Inc. | Butitta Cynthia M | COO | S - Sale+OE | $100.81 | -5,000 | 117,795 | -4% | -$504,033 | |||||
| D | 2017-06-23 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $109.09 | -4,000 | 2,800 | -59% | -$436,362 | |||||
2017-06-23 | KITE | Kite Pharma, Inc. | Butitta Cynthia M | COO | S - Sale | $100.81 | -5,000 | 112,795 | -4% | -$504,033 | ||||||
| DM | 2017-06-23 | KITE | Kite Pharma, Inc. | Witte Owen N. | Dir | S - Sale+OE | $100.30 | -25,000 | 76,250 | -25% | -$2,507,500 | |||||
| D | 2017-06-22 | SGEN | Seattle Genetics Inc /wa | Drachman Jonathan G | CMO, EVP, R, D | S - Sale+OE | $64.01 | -10,000 | 115,204 | -8% | -$640,058 | |||||
| M | 2017-06-22 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $16.23 | -32,368 | 2,569,446 | -1% | -$525,302 | |||||
| D | 2017-06-22 | CRSP | Crispr Therapeutics AG | Novak Rodger | CEO | S - Sale+OE | $15.37 | -10,825 | 1,215,005 | -1% | -$166,388 | |||||
| DM | 2017-06-20 | ONCE | Spark Therapeutics, Inc. | Marrazzo Jeffrey D | CEO | S - Sale+OE | $65.00 | -9,331 | 230,000 | -4% | -$606,515 | |||||
| M | 2017-06-20 | ONCE | Spark Therapeutics, Inc. | Mehra Anand | Dir | S - Sale | $65.00 | -6,302 | 693,128 | -1% | -$409,630 | |||||
| D | 2017-06-20 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $19.68 | -15,000 | 0 | -100% | -$295,157 | |||||
2017-06-20 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $19.68 | -6,500 | 118,500 | -5% | -$127,902 | ||||||
| D | 2017-06-20 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $120.03 | -2,500 | 2,800 | -47% | -$300,070 | |||||
2017-06-16 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $109.28 | -3,295 | 32,484 | -9% | -$360,085 | ||||||
| D | 2017-06-16 | BTX | Biotime Inc | Andrews Deborah J | Dir | P - Purchase | $2.95 | +2,000 | 6,000 | +50% | +$5,900 | |||||
| DM | 2017-06-19 | CRSP | Crispr Therapeutics AG | Novak Rodger | CEO | S - Sale+OE | $15.01 | -30,222 | 1,215,005 | -2% | -$453,511 | |||||
2017-06-20 | JUNO | Juno Therapeutics, Inc. | Evnin Anthony B | Dir | P - Purchase | $24.40 | +9,000 | 66,301 | +16% | +$219,600 | ||||||
| D | 2017-06-19 | ONCE | Spark Therapeutics, Inc. | High Katherine A | See Remarks | S - Sale+OE | $60.00 | -10,000 | 210,000 | -5% | -$600,000 | |||||
| D | 2017-06-19 | ONCE | Spark Therapeutics, Inc. | Webster Stephen W | CFO | S - Sale+OE | $60.00 | -7,663 | 2,500 | -75% | -$459,780 | |||||
2017-06-20 | NK | Nantkwest, Inc. | Thomas John C | Dir | S - Sale | $7.46 | -40,000 | 278,655 | -13% | -$298,500 | ||||||
2017-06-20 | NK | Nantkwest, Inc. | Gorlin Steve | Dir | S - Sale | $7.78 | -40,000 | 911,445 | -4% | -$311,200 | ||||||
2017-06-16 | MBOT | Microbot Medical Inc. | Lewkowicz Leon | 10% | S - Sale | $1.67 | -71,224 | 3,078,214 | -2% | -$118,944 | ||||||
2017-06-16 | ACOR | Acorda Therapeutics Inc | Cohen Ron | Pres, CEO | P - Purchase | $16.95 | +20,000 | 554,588 | +4% | +$338,998 | ||||||
2017-06-15 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $18.75 | -3,100 | 107,512 | -3% | -$58,125 | ||||||
2017-06-14 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Dir | S - Sale | $89.48 | -20,000 | 205,426 | -9% | -$1,789,574 | ||||||
| M | 2017-06-14 | KITE | Kite Pharma, Inc. | Champsi Farah | Dir | S - Sale | $89.79 | -20,450 | 63,664 | -24% | -$1,836,200 | |||||
2017-06-15 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $12.65 | -6,000 | 388,080 | -2% | -$75,900 | ||||||
| D | 2017-06-12 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $109.53 | -2,500 | 27,305 | -8% | -$273,831 | |||||
| D | 2017-06-09 | TECH | Bio-Techne Corp | Lucas Roger C | Dir | S - Sale+OE | $113.62 | -100 | 2,270 | -4% | -$11,362 | |||||
| D | 2017-06-09 | KITE | Kite Pharma, Inc. | Butitta Cynthia M | COO | S - Sale+OE | $88.55 | -10,000 | 117,795 | -8% | -$885,491 | |||||
| D | 2017-06-09 | ATRA | Atara Biotherapeutics, Inc. | Gallagher Carol Giltner | Dir | S - Sale+OE | $13.15 | -1,000 | 107,374 | -1% | -$13,150 | |||||
| DM | 2017-06-08 | CRSP | Crispr Therapeutics AG | Novak Rodger | CEO | S - Sale+OE | $15.02 | -5,303 | 1,215,005 | 0% | -$79,628 | |||||
| D | 2017-06-08 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $110.19 | -2,500 | 2,800 | -47% | -$275,488 | |||||
2017-06-09 | BIIB | Biogen Inc. | Posner Brian S | Dir | S - Sale | $256.31 | -1,084 | 6,330 | -15% | -$277,840 | ||||||
| M | 2017-06-07 | KITE | Kite Pharma, Inc. | Doumani Roy | Dir | S - Sale | $84.48 | -15,000 | 175,082 | -8% | -$1,267,255 | |||||
2017-06-07 | JUNO | Juno Therapeutics, Inc. | Klausner Richard | Dir | S - Sale | $23.60 | -24,000 | 824,605 | -3% | -$566,362 | ||||||
| D | 2017-06-07 | ONCE | Spark Therapeutics, Inc. | La Barge Joseph | GC | S - Sale+OE | $55.00 | -5,000 | 5,525 | -48% | -$275,000 | |||||
| M | 2017-06-06 | CDTX | Cidara Therapeutics, Inc. | Sandison Taylor | Chief Medical Officer | P - Purchase | $5.90 | +20,000 | 25,695 | +351% | +$118,000 | |||||
| D | 2017-06-06 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $100.05 | -2,500 | 27,305 | -8% | -$250,135 | |||||
| D | 2017-06-06 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $100.14 | -2,263 | 1,400 | -62% | -$226,622 | |||||
| D | 2017-06-06 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $99.04 | -1,500 | 35,779 | -4% | -$148,560 | |||||
| DM | 2017-06-06 | BLUE | Bluebird Bio, Inc. | Cole Jason | GC | S - Sale+OE | $100.22 | -17,245 | 31,602 | -35% | -$1,728,227 | |||||
| D | 2017-06-05 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $65.21 | -10,423 | 636,435 | -2% | -$679,698 | |||||
| D | 2017-06-05 | CELZ | Creative Medical Technology Holdings, Inc. | Warbington Timothy | Pres, CEO, 10% | S - Sale+OE | $0.30 | -5,300 | 65,072,594 | 0% | -$1,615 | |||||
| D | 2017-06-05 | CELZ | Creative Medical Technology Holdings, Inc. | Creative Medical Health Inc. | 10% | S - Sale+OE | $0.30 | -5,300 | 58,605,927 | 0% | -$1,615 | |||||
| D | 2017-06-05 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $90.00 | -1,000 | 1,400 | -42% | -$90,002 | |||||
| D | 2017-06-05 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $90.00 | -1,000 | 17,177 | -6% | -$90,002 | |||||
2017-06-05 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $5.95 | +15,000 | 248,618 | +6% | +$89,211 | ||||||
2017-06-06 | CBMG | Cellular Biomedicine Group, Inc. | Liu Tony | CEO, CFO | P - Purchase | $6.83 | +10,000 | 129,025 | +8% | +$68,348 | ||||||
2017-06-02 | EDIT | Editas Medicine, Inc. | Cox Gerald Frank | Chief Medical Officer | P - Purchase | $14.15 | +4,000 | 4,000 | New | +$56,600 | ||||||
2017-06-02 | EDIT | Editas Medicine, Inc. | Nikolic Boris | Dir | P - Purchase | $14.07 | +35,000 | 2,684,572 | +1% | +$492,527 | ||||||
2017-06-02 | TCON | Tracon Pharmaceuticals, Inc. | Larue William R | Dir | S - Sale | $2.69 | -2,500 | 13,388 | -16% | -$6,733 | ||||||
| D | 2017-06-01 | GILD | Gilead Sciences Inc | Martin John C | Exec COB | S - Sale+OE | $65.24 | -73,333 | 3,199,969 | -2% | -$4,784,531 | |||||
2017-06-01 | GILD | Gilead Sciences Inc | Alton Gregg H | EVP Comm, Acs ALA, Corp, Med A | S - Sale | $65.02 | -5,000 | 107,988 | -4% | -$325,114 | ||||||
| D | 2017-06-02 | CELZ | Creative Medical Technology Holdings, Inc. | Warbington Timothy | Pres, CEO, 10% | S - Sale+OE | $0.41 | -5,700 | 65,077,894 | 0% | -$2,324 | |||||
| D | 2017-06-02 | CELZ | Creative Medical Technology Holdings, Inc. | Creative Medical Health Inc. | 10% | S - Sale+OE | $0.41 | -5,700 | 58,611,227 | 0% | -$2,324 | |||||
| D | 2017-06-01 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Development | S - Sale+OE | $72.45 | -2,400 | 18,664 | -11% | -$173,880 | |||||
| D | 2017-06-01 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $75.62 | -1,500 | 36,279 | -4% | -$113,430 | |||||
| D | 2017-06-01 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $75.42 | -2,000 | 17,177 | -10% | -$150,849 | |||||
2017-06-01 | CHRS | Coherus Biosciences, Inc. | Herman Alan C. | Chief Scientific Officer | S - Sale | $20.32 | -11,333 | 367,950 | -3% | -$230,292 | ||||||
2017-06-01 | SGMO | Sangamo Therapeutics, Inc | Herberts Curt A. III | SVP, CBO | S - Sale | $6.80 | -2,000 | 35,345 | -5% | -$13,600 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |